AZN Stock Summary and Trading Ideas (Astrazeneca PLC | NYSE:AZN)

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Astrazeneca PLC trades on the NYSE stock market under the symbol AZN.

As of May 22, 2026, AZN stock price declined to $187.03 with 1,502,151 million shares trading.

AZN has a beta of 0.00, meaning it tends to be less sensitive to market movements. AZN has a correlation of 0.00 to the broad based SPY ETF.

AZN has a market cap of $289.95 billion. This is considered a Mega Cap stock.

Last quarter Astrazeneca PLC reported $15 billion in Revenue and $2.58 earnings per share. This beat revenue expectation by $358 million and exceeded earnings estimates by $1.05.

In the last 3 years, AZN traded as high as $212.71 and as low as $60.47.

The top ETF exchange traded funds that AZN belongs to (by Net Assets): PVAL, AVDE, DIHP, DFIC, PPH.

AZN has outperformed the market in the last year with a price return of +177.4% while the SPY ETF gained +29.1%. However, in the short term, AZN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -8.4% vs +8.4% return in SPY. But in the last 2 weeks, AZN shares have fared better than the market returning +2.3% compared to SPY +1.1%.

AZN support price is $186.99 and resistance is $192.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZN shares will trade within this expected range on the day.